The US investment bank says the phase 3 results in ovarian cancer change its view of the drug candidate and still point to ...

AbbVie will test lutikizumab together with ABBV-295, the amylin-based obesity drug it licensed from Danish biotech Gubra, ...

China has more house dust mite allergy sufferers than any other country, but fewer than 1 million of an estimated 100 million ...

EU panel backs Eli Lilly’s Foundayo obesity pill Eli Lilly is still awaiting final approval from the European Commission.

All major hearing aid makers are launching new premium devices at the same time, but Søren Nielsen expects audiologists to ...

Viatris to buy Pacira for USD 1.65bn, adding two non-opioid pain drugs The all-cash deal values Pacira Biosciences at USD 36.50 a share, a 45% premium, and brings Exparel and Zilretta into Viatris’ ...

PhRMA sues Trump administration to block Medicare drug pricing program The drug industry lobby says the Globe program, which ties some Medicare prices to prices abroad, oversteps the agency’s ...

Former GN executive to lead Nordic expansion of AI cell-therapy company that took over Novo program Peter Aksel Villadsen leaves GN after six years to build up Cellular Intelligence in the Nordics, as ...

Bavarian Nordic CFO says latest guidance upgrade vindicates GSK vaccine deal Thursday’s upgrade is driven almost entirely by stronger US sales of the company’s rabies vaccine, which Bavarian Nordic ...